Canopy Growth’s Medical Market Push Offers Counterweight to Regulatory Whiplash

Canopy Growth quietly expands Spectrum Therapeutics softgel pack sizes, targeting prescription revenue, while US rescheduling offers limited direct benefit for the Canadian producer.

Canopy Growth is playing a long game in medical cannabis, quietly expanding its softgel lineup while the market fixates on the noisy aftermath of a US policy shift. On May 7, the company announced new 30- and 90-unit packs for its Minor Cannabinoid Softgels, alongside additional dosing options under the Spectrum Therapeutics banner. The move is unglamorous — but it targets the kind of repeat, prescription-driven revenue that has become critical for the Canadian producer.

The rationale is straightforward: medical patients and prescribers value consistent dosing and convenient packaging. The larger pack sizes offer better value and flexibility, building on demand for the existing smaller formats. Spectrum Therapeutics, Canopy’s medical arm, serves Canada and select international markets with dried flower, oils, edibles, and capsules. By sharpening the softgel offering rather than launching wholly new products, Canopy is doubling down on a segment that generates more predictable income than the volatile recreational market.

That disciplined approach contrasts sharply with the stock’s behavior just weeks earlier. On April 23, 2026, the US Department of Justice and the DEA rescheduled cannabis to Schedule III of the Controlled Substances Act, fulfilling President Trump’s December 2025 executive order. Canopy Growth shares shot up 28% to $1.51 before sliding back to roughly $1.18. The retreat was structural: as a Canadian operator, Canopy has no direct US cultivation or distribution. Its exposure runs through an equity structure called Canopy USA, which holds stakes in brands like Wana and Jetty via exchangeable shares — an indirect and less immediate channel.

The Schedule III reclassification does bring tangible relief for US cannabis companies, mainly by eliminating the punitive 280E tax rule that prevented operators from deducting ordinary business expenses. An analyst described the old tax burden as “a significant headwind to earnings profiles and free cash flow.” But the current order applies only to FDA-approved, state-licensed medical products. Adult-use cannabis remains Schedule I, still subject to 280E. The broader rule change faces a DEA hearing beginning June 29, 2026, with a conclusion required by July 15. A final determination could land by end of 2026, though legal challenges could stretch the timeline into 2027 or beyond.

Meanwhile, Canopy’s own turnaround is showing measurable progress. Over the trailing twelve months, net losses totaled CAD 327 million, but the third quarter of fiscal 2026 saw the net loss shrink 49% year-over-year. Adjusted operating losses narrowed to just CAD 3 million, on revenue of CAD 74.5 million. The balance sheet holds roughly CAD 371 million in cash. The company is relying on its acquisition of MTL Cannabis to accelerate the trajectory: management expects the deal to contribute around CAD 84 million in annual revenue, and is targeting positive adjusted EBITDA by fiscal 2027.

That target faces a critical test on May 29, when Canopy reports full-year results — the first print to include a full quarter of MTL contribution. Analysts will scrutinize whether the promised margin improvements are materializing. If the operating loss does not shrink further, the path to profitability in 2027 looks steeper. The stock currently trades between $1.11 and $1.15 on the Nasdaq, far below its 52-week high of $2.38.

Between the earnings release in late May and the DEA hearing in late June, Canopy confronts a dense calendar of catalysts. The softgel portfolio expansion is a modest but deliberate step toward building recurring medical revenue. It will not, on its own, transform the investment case. But it signals a management team focused on operational granularity — smaller packs, better margins, less reliance on headline-driven rallies. Whether that is enough to bridge the gap to profitability will be decided in the numbers, not the news flow.